SANDY — Utah-based MediConnect Global Inc., a leading provider of proprietary systems and services that facilitate the aggregation and analysis of medical records, was purchased by Verisk Analytics in a nearly $350 million deal Friday.
Verisk officials say the acquisition will help advance its position as a major provider of data, analytics and decision support solutions in the healthcare industry.
"MediConnect has developed unique solutions for health plans to meet critical regulatory requirements, evaluate quality of care and enhance the efficiency of reporting and analytics," said Frank Coyne, chairman and chief executive officer of Verisk Analytics. "We believe MediConnect's capabilities and extensive clinical data repository will align naturally with our Verisk health solutions … (and create) a more comprehensive offering for our clients and incremental revenue opportunities for our enterprise."
Amy Rees Anderson, who has headed MediConnect in Sandy since 2004, will continue to lead the company.
"We're very excited to join forces with Verisk," said Anderson, MediConnect's chief executive officer. "The merger will provide our customers with industry-leading, comprehensive health data and analytics from a single source."
MediConnect has a repository of nearly 10 million medical records that are digitized, indexed and securely hosted online. It uses custom-built proprietary technology to deliver medical records from facilities and provider locations across six continents.
The company’s clients access the clinical data through a cloud-based workflow management system. MediConnect also offers scheduling, retrieval, review, data validation and analytics.1 comment on this story
"Combining MediConnect’s innovative systems and services with Verisk’s extensive data analytics will provide a turnkey solution that will transform the way the healthcare industry manages medical costs and improves the quality of care," Anderson said.
The net purchase price is $348.6 million. As part of the transaction, Verisk expects to realize approximately $25 million in tax and positive working capital benefits. The transaction is expected to close in March 2012, subject to the completion of customary closing conditions, including receipt of MediConnect shareholder and regulatory approvals.
Verisk will use cash on hand and available capacity under its revolving credit facility to fund the purchase.